2 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow imdevimab: new trials by email Literature Review of imdevimab trials Research Report on imdevimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACTIV-2: A Study for Outpatients With COVID-19 bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19 | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 4044 | 2020-08-19 | 2024-08-02 |
| COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay REGN10933 + REGN10987, Placebo - Healthy Participants | Phase 3 | Completed | Regeneron Pharmaceuticals | 3303 | 2020-07-13 | 2023-05-15 |
COVID-19 (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Nidovirales Infections (1) · RNA Virus Infections (1) · Severe Acute Respiratory Syndrome (1) · Virus Diseases (1)
National Institute of Allergy and Infectious Diseases (NIAID) (1) · Regeneron Pharmaceuticals (1)
United States (2) · Argentina (1) · Brazil (1) · Canada (1) · Guatemala (1) · Mexico (1) · Moldova (1) · Philippines (1) · Puerto Rico (1) · Romania (1) · South Africa (1)
PMID 34473343, PMID 35713300, PMID 34159343, PMID 34159344, PMID 34347950, PMID 34981077, PMID 35029629, PMID 35793677, PMID 35797235, PMID 35803290, PMID 35995785, PMID 36210483, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36802755, PMID 37068272, PMID 37099295, PMID 37279602, PMID 37330602, PMID 37650230, PMID 37650232, PMID 37650233, PMID 37650236, PMID 37855026, PMID 39018444, PMID 39028902, PMID 42148571